Quote:

---

f CCR5 blockade is completely protective against covid, as it is against the most common HIV strain, then there will be zero double CCR5delta32 mutants in any covid trial.

Because just as with HIV, double CCR5 mutants are immune.

So if the theory is true

---

It isn't. The double allele mutation is protective in HIV because HIV binds to CCR5 to invade the cells. No invasion, no reproduction. COVID binds to ACE2 so it's free to invade the cell because obviously a CCR5 mutation is not an ACE2 mutation.

As far as protection against immune overreaction CCR5 delta32 double allele would provide some protection against it but it's not 100%. With double allele what happens is CCR1 and CCR3 would take over for CCR5. In non-mutation people CCR1 and CCR3 is produced less and has lesser binding efficiency than CCR5.

From an evolutionary standpoint those with double allele mutations would have to have CCR1 and CCR3 increase in numbers and/or binding or otherwise the double allele mutation would have died out because of lack of immune protection.

Even with a lesser immune response in double allele that doesn't mean it won't ramp up to a severe reaction for COVID.

Quote:

---

So every covid clinical trial has about 10% of its participants who are single mutants, and theoretically those 10% should respond better to LL.

---

Worldwide it is much less than 10%. If our coverage of CCR5 is over 90% there should be little difference between non-mutation and single allele mutation because at most there is 10% difference in effect.